Prostaglandin biochemistry of seeded endothelial cells on Dacron prostheses.
The beneficial effect of seeding endothelial cells on synthetic vascular conduits has been well established. The biochemical production and interaction of the prostaglandins, prostacyclin (PGI2) and thromboxane (TxA2), were studied on Dacron vascular grafts that were seeded with autogenous venous endothelial cells. Seventy-three seeded and nonseeded grafts were implanted into the carotid arteries of dogs. Animals were medicated with either cyclooxygenase inhibitors (aspirin and dipyridamole, or ibuprofen, or U-53,059), or dipyridamole alone, or a thromboxane synthase inhibitor, U-63557A. All animals were killed at 5 weeks and analyzed for patency, thrombus-free surface (TFS), and PGI2 and TxA2 production from mid-graft punch biopsies. PGI2 and TxA2 identifications were made by radioimmunoassay determination of 6-keto PGF1 alpha and TxB2, respectively. Results of the study demonstrated in nonmedicated animals a slightly increased patency rate in seeded vs. nonseeded grafts (50% vs. 40%) and a more significant difference in TFS (49% vs. 24%). The addition of cyclooxygenase inhibitors or TxA2 synthase inhibitors significantly improved both patency (90% vs. 47%) and TFS (87% vs. 9%) in seeded vs. nonseeded grafts. PGI2 production was decreased in seeded grafts with the use of cyclooxygenase inhibitors in all cases. It is concluded that seeded endothelial cells on Dacron velour grafts can synthesize PGI2; these PGI2 levels are far less than PGI2 levels produced by endothelial cells from the adjacent carotid artery; and TxA2 synthase inhibitors best improve thromboresistance of seeded grafts without significant reduction in PGI2 production.
D000818:Animals; D001807:Blood Vessel Prosthesis; D016861:Cyclooxygenase Inhibitors; D004285:Dogs; D004727:Endothelium / Q000166:cytology / Q000378:metabolism*; D011464:Epoprostenol / Q000096:biosynthesis; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011093:Polyethylene Terephthalates; D011453:Prostaglandins / Q000096:biosynthesis*; D013928:Thromboxane A2 / Q000096:biosynthesis; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
D016861:Cyclooxygenase Inhibitors; D010726:Phosphodiesterase Inhibitors; D011093:Polyethylene Terephthalates; D011453:Prostaglandins; D013928:Thromboxane A2; D011464:Epoprostenol; D013930:Thromboxane-A Synthase